5 Best Biotech Stocks to Buy According to Alan Frazier

In this article, we discuss the 5 best dividend stocks to buy according to Alan Frazier. If you want to read our detailed analysis of Frazier’s history and hedge fund performance, go directly to the 10 Best Biotech Stocks to Buy According to Alan Frazier. 

5. Epizyme, Inc. (NASDAQ: EPZM)

Frazier’s Stake Value: $6,440,000
Percentage of Alan Frazier’s 13F Portfolio: 0.51%
Number of Hedge Fund Holders: 16

Epizyme, Inc. (NASDAQ: EPZM) is an American biopharmaceutical company, which discovers, develops, and sells medicines for patients with cancer and other diseases. The company was incorporated in 2007 and is ranked fifth on the list of 10 best biotech stocks to buy according to Alan Frazier. Epizyme currently has a market capitalization of $872.91.

On May 7, Andrew Berens, an analyst at SVB Leerink, initiated coverage on Epizyme (NASDAQ: EPZM), rating the stock as “Outperform,” with a price target of $16. On May 6, the company posted revenue for the first quarter of 2021. It declared revenue of $7.63 million, up 465.2% YoY, beating the estimates by $0.76 million. 

The hedge fund chaired by Frazier holds 739,369 shares in the company worth $6.44 million. Frazier Healthcare Partners increased its stake in Epizyme, Inc. (NASDAQ: EPZM) by 2% in the past few months. Redmile Group owns 8.82 million shares of Epizyme (NASDAQ: EPZM), worth $76.86 million, topping the list of over 850 hedge funds tracked by Insider Monkey.